FDA Delays Decision On KalVista's Sebetralstat NDA For Hereditary Angioedema
14/6 05:55
(RTTNews) - KalVista Pharmaceuticals Inc. (KALV) announced Friday now that the U.S. Food and Drug Administration has notified the company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the company's investigational oral on-demand t...